Molecular mechanisms of sorafenib action in liver cancer cells
Volume 11, Issue 15
Purchase or Subscribe
August 1, 2012
Pages 2843 - 2855http://dx.doi.org/10.4161/cc.21193
: Acheron/LARP6, Dickkopf1, HCC, Harakiri, YAP1, cell cycle, global gene expression analysis, microarray, mini-chromosome maintenance genes, sorafenib
Authors: Melchiorre Cervello, Dimcho Bachvarov, Nadia Lampiasi, Antonella Cusimano, Antonina Azzolina, James A. McCubrey and Giuseppe Montalto View affiliations
Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib evolves, there is increasing interest in defining the mechanisms underlying its anti-tumor activity. Considering that this specific inhibitor could target unexpected molecules depending on the biologic context, a precise understanding of its mechanism of action could be critical to maximize its treatment efficacy, while minimizing adverse effects. Two human HCC cell lines (HepG2 and Huh7), carrying different biological and genetic characteristics, were used in this study to examine the intracellular events leading to sorafenib-induced HCC cell-growth inhibition. Sorafenib inhibited cell growth in both cell lines in a dose- and time-dependent manner and significantly altered expression levels of 826 and 2011 transcripts in HepG2 and Huh7 cells, respectively. Genes functionally involved in angiogenesis, apoptosis, transcription regulation, signal transduction, protein biosynthesis and modification were predominantly upregulated, while genes implicated in cell cycle control, DNA replication recombination and repair, cell adhesion, metabolism and transport were mainly downregulated upon treatment. However, each sorafenib-treated HCC cell line displayed specificity in the expression and activity of crucial factors involved in hepatocarcinogenesis. The altered expression of some of these genes was confirmed by semiquantitative and quantitative RT-PCR and by western blotting. Many novel genes emerged from our transcriptomics analysis that had not previously been reported to be effected by sorafenib. Further functional analyses may determine whether these genes can serve as potential molecular targets for more effective anti-HCC strategies.
Received: April 24, 2012; Accepted: June 20, 2012
Full Text - Ahead of Print Available - Log in!